Genomic Health (GHDX) appears to be quite an impressive small-cap biotech stock operating in the high growth potential cancer market. The company develops genomic-based clinical diagnostic tests. Basically, GHDX's products allow for the individualized treatment of cancer. To date, GHDX has helped more than 375,000 cancer patients worldwide in their treatment decisions. With the innovative products in the company's pipeline, the upside could be impressive over the next couple of years as GHDX expands into other huge opportunity cancer markets.
GHDX's staple cancer test, Oncotype DX
For 2Q, the company posted EPS of a $0.10 loss, compared to the $0.06 loss for the same period last year. The company delivered 20,640 Oncotype...
Only subscribers can access this article, which is part of the PRO research library covering 3,608 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: